A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Clinical trial NCT06385925 · RECRUITING
Trial details
- NCT number
- NCT06385925
- Sponsor
- Tyligand Pharmaceuticals (Suzhou) Limited
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-29
- Primary completion
- 2026-10-30
- Enrollment
- 440
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.